Jan 12, 2025, 13:43
Dipesh Uprety: TROPION-Lung05 – a phase II trial on NSCLC by Jacob Sands et al.
Dipesh Uprety, Assistant Professor of Thoracic Oncology at Karmanos Cancer Institute, shared a post on X about recent paper by Jacob Sands, Medical oncologist at Dana-Farber Cancer Institute, published in Journal of Clinical Oncology:
“TROPION-Lung05: a phase II trial.
Patients with advanced/metastatic NSCLC with actionable genomic alterations after disease progression on targeted therapy and chemotherapy received Dato-DXd.
ORR 35.8%, DCR 78.8%, Median DoR 7 months.”
Authors: Jacob Sands, Myung-Ju Ahn, Aaron Lisberg, Rachel Chiaverelli, Luis Paz-Ares, et al.
More posts featuring Dipesh Uprety.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 12, 2025, 12:59
Jan 12, 2025, 12:33
Jan 12, 2025, 12:30
Jan 12, 2025, 12:17
Jan 12, 2025, 11:50
Jan 12, 2025, 11:20
Jan 12, 2025, 11:19